{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:54:25Z","timestamp":1793836465141,"version":"4.6.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00415-020-10264-0","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T06:03:09Z","timestamp":1602828189000},"page":"4573-4586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review"],"prefix":"10.1007","volume":"268","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4015-9783","authenticated-orcid":false,"given":"Itay","family":"Lotan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Wilf-Yarkoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"issue":"3","key":"10264_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1055\/s-0032-1329200","volume":"32","author":"NJ Silvestri","year":"2012","unstructured":"Silvestri NJ, Wolfe GI (2012) Myasthenia gravis. Semin Neurol 32(3):215\u2013226","journal-title":"Semin Neurol"},{"issue":"26","key":"10264_CR2","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375(26):2570\u20132581","journal-title":"N Engl J Med"},{"issue":"10","key":"10264_CR3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023\u20131036","journal-title":"Lancet Neurol"},{"issue":"4","key":"10264_CR4","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s00415-015-7963-5","volume":"263","author":"S Binks","year":"2016","unstructured":"Binks S, Vincent A, Palace J (2016) Myasthenia gravis: a clinical-immunological update. J Neurol 263(4):826\u2013834","journal-title":"J Neurol"},{"key":"10264_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","volume":"52","author":"P Zisimopoulou","year":"2014","unstructured":"Zisimopoulou P, Evangelakou P, Tzartos J, Lazaridis K, Zouvelou V, Mantegazza R et al (2014) A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 52:139\u2013145","journal-title":"J Autoimmun"},{"issue":"1","key":"10264_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00415-010-5746-6","volume":"258","author":"Z Argov","year":"2011","unstructured":"Argov Z (2011) Current approach to seronegative myasthenia. J Neurol 258(1):14\u201318","journal-title":"J Neurol"},{"issue":"10","key":"10264_CR7","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1136\/jnnp-2014-309236.176","volume":"85","author":"S Huda","year":"2014","unstructured":"Huda S, Koneczny I, Jacobsen L, Beeson D, Vincent A (2014) Seronegative myasthenia gravis-clinical\/serological aspects. J Neurol Neurosur Psychiatry 85(10):e4","journal-title":"J Neurol Neurosur Psychiatry"},{"issue":"6","key":"10264_CR8","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1001\/jamaneurol.2015.0205","volume":"72","author":"S Vernino","year":"2015","unstructured":"Vernino S (2015) Unraveling the enigma of seronegative myasthenia gravis. JAMA Neurol 72(6):630\u2013631","journal-title":"JAMA Neurol"},{"issue":"12","key":"10264_CR9","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1212\/01.WNL.0000098887.24618.A0","volume":"61","author":"DP Richman","year":"2003","unstructured":"Richman DP, Agius MA (2003) Treatment of autoimmune myasthenia gravis. Neurology 61(12):1652\u20131661","journal-title":"Neurology"},{"issue":"2","key":"10264_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/1756285608093888","volume":"1","author":"R Gold","year":"2008","unstructured":"Gold R, Hohlfeld R, Toyka KV (2008) Progress in the treatment of myasthenia gravis. Ther Adv Neurol Disord 1(2):36\u201351","journal-title":"Ther Adv Neurol Disord"},{"key":"10264_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jns.2016.08.057","volume":"369","author":"L Gotterer","year":"2016","unstructured":"Gotterer L, Li Y (2016) Maintenance immunosuppression in myasthenia gravis. J Neurol Sci 369:294\u2013302","journal-title":"J Neurol Sci"},{"issue":"1","key":"10264_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J (2019) Myasthenia gravis. Nat Rev Dis Primers 5(1):30","journal-title":"Nat Rev Dis Primers"},{"key":"10264_CR13","first-page":"847393","volume":"2011","author":"NE Gilhus","year":"2011","unstructured":"Gilhus NE, Owe JF, Hoff JM, Romi F, Skeie GO, Aarli JA (2011) Myasthenia gravis: a review of available treatment approaches. Autoimmune Dis 2011:847393","journal-title":"Autoimmune Dis"},{"issue":"1","key":"10264_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3181\/00379727-57-14730","volume":"57","author":"C Torda","year":"1944","unstructured":"Torda C, Wolff HG (1944) Effect of adrenotrophic hormone of pituitary gland on ability of tissue to synthesize acetylcholine. Proc Soc Exp Biol Med 57(1):137\u2013139","journal-title":"Proc Soc Exp Biol Med"},{"issue":"2","key":"10264_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/archneurpsyc.1951.02320080047004","volume":"66","author":"C Torda","year":"1951","unstructured":"Torda C, WOLFF HG, (1951) Effects of administration of the adrenocorticotropic hormone (ACTH) on patients with myasthenia gravis. AMA Arch Neurol Psychiatry 66(2):163\u2013170","journal-title":"AMA Arch Neurol Psychiatry"},{"issue":"3","key":"10264_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1212\/WNL.1.3.145","volume":"1","author":"CH Millikan","year":"1951","unstructured":"Millikan CH, Eaton LM (1951) Clinical evaluation of ACTH and cortisone in myasthenia gravis. Neurology 1(3):145","journal-title":"Neurology"},{"issue":"2","key":"10264_CR17","first-page":"124","volume":"91","author":"D Grob","year":"1952","unstructured":"Grob D, Harvey A (1952) Effect of adrenocorticotropic hormone (ACTH) and cortisone administration in patients with myasthenia gravis and report of onset of myasthenia gravis during prolonged cortisone administration. Bull Johns Hopkins Hosp 91(2):124","journal-title":"Bull Johns Hopkins Hosp"},{"issue":"7","key":"10264_CR18","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/jama.1952.02930070008003","volume":"148","author":"N Schlezinger","year":"1952","unstructured":"Schlezinger N (1952) Present status of therapy in myasthenia gravis. J Am Med Assoc 148(7):508\u2013513","journal-title":"J Am Med Assoc"},{"issue":"10","key":"10264_CR19","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1212\/WNL.21.10.1008","volume":"21","author":"T Namba","year":"1971","unstructured":"Namba T, Brunner NG, Shapiro MS, Grob D (1971) Corticotropin therapy in myasthenia gravis: effects, indications, and limitations. Neurology 21(10):1008\u20131018","journal-title":"Neurology"},{"issue":"6","key":"10264_CR20","first-page":"966","volume":"36","author":"CH Millikan","year":"1950","unstructured":"Millikan CH, Eaton LM (1950) Clinical evaluation of the effect of adrenocorticotrophic hormone and cortisone on myasthenia gravis. J Lab Clin Med 36(6):966\u2013967","journal-title":"J Lab Clin Med"},{"issue":"1","key":"10264_CR21","first-page":"3","volume":"27","author":"ED Mc","year":"1951","unstructured":"Mc ED (1951) Diseases and disorders of muscle function. Bull N Y Acad Med 27(1):3\u201323","journal-title":"Bull N Y Acad Med"},{"issue":"16","key":"10264_CR22","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.1950.02920160027006","volume":"144","author":"GM Shy","year":"1950","unstructured":"Shy GM, Brendler S, Rabinovitch R, Mc ED (1950) Effects of cortisone in certain neuromuscular disorders. J Am Med Assoc 144(16):1353\u20131358","journal-title":"J Am Med Assoc"},{"key":"10264_CR23","first-page":"1","volume":"2","author":"C Schneider-Gold","year":"2005","unstructured":"Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR (2005) Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev 2:1","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10264_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1056\/NEJM197201062860104","volume":"286","author":"JR Warmolts","year":"1972","unstructured":"Warmolts JR, Engel WK (1972) Benefit from alternate-day prednisone in myasthenia gravis. N Engl J Med 286(1):17\u201320","journal-title":"N Engl J Med"},{"key":"10264_CR25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1749-6632.1971.tb30743.x","volume":"183","author":"WK Engel","year":"1971","unstructured":"Engel WK, Warmolts JR (1971) Myasthenia gravis: a new hypothesis of the pathogenesis and a new form of treatment. Ann N Y Acad Sci 183:72\u201387","journal-title":"Ann N Y Acad Sci"},{"issue":"7684","key":"10264_CR26","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/S0140-6736(70)90392-2","volume":"2","author":"JR Warmolts","year":"1970","unstructured":"Warmolts JR, Engel WK, Whitaker JN (1970) Alternate-dy prednisone in a patient with myasthenia gravis. Lancet 2(7684):1198\u20131199","journal-title":"Lancet"},{"issue":"2","key":"10264_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1056\/NEJM197401102900204","volume":"290","author":"ME Seybold","year":"1974","unstructured":"Seybold ME, Drachman DB (1974) Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N Engl J Med 290(2):81\u201384","journal-title":"N Engl J Med"},{"issue":"2","key":"10264_CR28","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1212\/WNL.34.2.170","volume":"34","author":"A Sghirlanzoni","year":"1984","unstructured":"Sghirlanzoni A, Peluchetti D, Mantegazza R, Fiacchino F, Cornelio F (1984) Myasthenia gravis: prolonged treatment with steroids. Neurology 34(2):170\u2013174","journal-title":"Neurology"},{"issue":"7754","key":"10264_CR29","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S0140-6736(72)90520-X","volume":"1","author":"RB Jenkins","year":"1972","unstructured":"Jenkins RB (1972) Treatment of myasthenia gravis with prednisone. Lancet 1(7754):765\u2013767","journal-title":"Lancet"},{"issue":"3","key":"10264_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000114612","volume":"12","author":"P Pinelli","year":"1974","unstructured":"Pinelli P, Tonali P, Scoppetta C (1974) Long-term treatment of myasthenia gravis with alternate-day prednisone. Report on 15 patients. Eur Neurol 12(3):129\u2013141","journal-title":"Eur Neurol"},{"issue":"11","key":"10264_CR31","first-page":"631","volume":"290","author":"MP McQuillen","year":"1974","unstructured":"McQuillen MP (1974) Letter: prednisone schedule for myasthenia gravis. N Engl J Med 290(11):631\u2013632","journal-title":"N Engl J Med"},{"issue":"1","key":"10264_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000116785","volume":"32","author":"A Evoli","year":"1992","unstructured":"Evoli A, Batocchi AP, Palmisani MT, Lo Monaco M, Tonali P (1992) Long-term results of corticosteroid therapy in patients with myasthenia gravis. Eur Neurol 32(1):37\u201343","journal-title":"Eur Neurol"},{"issue":"3","key":"10264_CR33","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.410150316","volume":"15","author":"RM Pascuzzi","year":"1984","unstructured":"Pascuzzi RM, Coslett HB, Johns TR (1984) Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 15(3):291\u2013298","journal-title":"Ann Neurol"},{"issue":"1","key":"10264_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000322497","volume":"65","author":"Y Nagane","year":"2011","unstructured":"Nagane Y, Suzuki S, Suzuki N, Utsugisawa K (2011) Early aggressive treatment strategy against myasthenia gravis. Eur Neurol 65(1):16\u201322","journal-title":"Eur Neurol"},{"issue":"6","key":"10264_CR35","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/mus.25397","volume":"55","author":"K Utsugisawa","year":"2017","unstructured":"Utsugisawa K, Nagane Y, Akaishi T, Suzuki Y, Imai T, Tsuda E et al (2017) Early fast-acting treatment strategy against generalized myasthenia gravis. Muscle Nerve 55(6):794\u2013801","journal-title":"Muscle Nerve"},{"issue":"1","key":"10264_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/mus.1221","volume":"25","author":"RS Bedlack","year":"2002","unstructured":"Bedlack RS, Sanders DB (2002) Steroid treatment for myasthenia gravis: steroids have an important role. Muscle Nerve 25(1):117\u2013121","journal-title":"Muscle Nerve"},{"issue":"7","key":"10264_CR37","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/jnnp.43.7.644","volume":"43","author":"LP Rowland","year":"1980","unstructured":"Rowland LP (1980) Controversies about the treatment of myasthenia gravis. J Neurol Neurosurg Psychiatry 43(7):644\u2013659","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10264_CR38","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/j.1749-6632.1976.tb47719.x","volume":"274","author":"J Mann","year":"1976","unstructured":"Mann J, Johns T, Campa J, Muller W (1976) Long-term prednisone followed by thymectomy in myasthenia gravis. Ann N Y Acad Sci 274:608\u2013622","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"10264_CR39","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1212\/WNL.24.8.795","volume":"24","author":"KC Fischer","year":"1974","unstructured":"Fischer KC, Schwartzman RJ (1974) Oral corticosteroids in the treatment of ocular myasthenia gravis. Neurology 24(8):795","journal-title":"Neurology"},{"key":"10264_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jns.2018.10.018","volume":"396","author":"T Kanai","year":"2019","unstructured":"Kanai T, Uzawa A, Kawaguchi N, Oda F, Ozawa Y, Himuro K et al (2019) Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis. J Neurol Sci 396:8\u201311","journal-title":"J Neurol Sci"},{"issue":"1","key":"10264_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/BF00313263","volume":"222","author":"C Scoppetta","year":"1979","unstructured":"Scoppetta C, Tonali P, Evoli A, David P, Crucitti F, Vaccario M (1979) Treatment of myasthenia gravis. J Neurol 222(1):11\u201321","journal-title":"J Neurol"},{"key":"10264_CR42","first-page":"99","volume":"17","author":"T Johns","year":"1977","unstructured":"Johns T (1977) Treatment of myasthenia gravis: long-term administration of corticosteroids with remarks on thymectomy. Adv Neurol 17:99\u2013122","journal-title":"Adv Neurol"},{"key":"10264_CR43","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/j.1749-6632.1976.tb47718.x","volume":"274","author":"JF Howard","year":"1976","unstructured":"Howard JF, Duane DD, Lambert EH, Daube JR (1976) Alternate-day prednisone: preliminary report of a double-blind controlled study. Ann N Y Acad Sci 274:596\u2013607","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"10264_CR44","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jocn.2005.12.041","volume":"13","author":"JS Bae","year":"2006","unstructured":"Bae JS, Go SM, Kim BJ (2006) Clinical predictors of steroid-induced exacerbation in myasthenia gravis. J Clin Neurosci 13(10):1006\u20131010","journal-title":"J Clin Neurosci"},{"issue":"4","key":"10264_CR45","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1600-0404.1971.tb07501.x","volume":"47","author":"M Kj\u00e6r","year":"1971","unstructured":"Kj\u00e6r M (1971) Myasthenia gravis and myasthenic syndromes treated with prednisone. Acta Neurol Scand 47(4):464\u2013474","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"10264_CR46","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1212\/WNL.22.6.603","volume":"22","author":"NG Brunner","year":"1972","unstructured":"Brunner NG, Namba T, Grob D (1972) Corticosteroids in management of severe, generalized myasthenia gravis: effectiveness and comparison with corticotropin therapy. Neurology 22(6):603","journal-title":"Neurology"},{"issue":"12","key":"10264_CR47","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1001\/archneur.1985.04060110031011","volume":"42","author":"E Arsura","year":"1985","unstructured":"Arsura E, Brunner NG, Namba T, Grob D (1985) High-dose intravenous methylprednisolone in myasthenia gravis. Arch Neurol 42(12):1149\u20131153","journal-title":"Arch Neurol"},{"key":"10264_CR48","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jns.2019.05.003","volume":"402","author":"Y Ozawa","year":"2019","unstructured":"Ozawa Y, Uzawa A, Kanai T, Oda F, Yasuda M, Kawaguchi N et al (2019) Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis. J Neurol Sci 402:12\u201315","journal-title":"J Neurol Sci"},{"issue":"2","key":"10264_CR49","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1136\/jnnp.68.2.214","volume":"68","author":"A Komiyama","year":"2000","unstructured":"Komiyama A, Arai H, Kijima M, Hirayama K (2000) Extraocular muscle responses to high dose intravenous methylprednisolone in myasthenia gravis. J Neurol Neurosurg Psychiatry 68(2):214\u2013217","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10264_CR50","doi-asserted-by":"publisher","first-page":"116740","DOI":"10.1016\/j.jns.2020.116740","volume":"412","author":"T Sugimoto","year":"2020","unstructured":"Sugimoto T, Ochi K, Ishikawa R, Tazuma T, Hayashi M, Mine N et al (2020) Initial deterioration and intravenous methylprednisolone therapy in patients with myasthenia gravis. J Neurol Sci 412:116740","journal-title":"J Neurol Sci"},{"issue":"6","key":"10264_CR51","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1600-0404.1998.tb05968.x","volume":"97","author":"C Lindberg","year":"1998","unstructured":"Lindberg C, Andersen O, Lefvert A (1998) Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol Scand 97(6):370\u2013373","journal-title":"Acta Neurol Scand"},{"key":"10264_CR52","volume-title":"Myasthenia gravis","author":"K Osserman","year":"1958","unstructured":"Osserman K (1958) Myasthenia gravis. Grune & Stratton. Inc, New York"},{"issue":"6","key":"10264_CR53","first-page":"497","volume":"38","author":"KE Osserman","year":"1971","unstructured":"Osserman KE, Genkins G (1971) Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 38(6):497\u2013537","journal-title":"Mt Sinai J Med"},{"issue":"1","key":"10264_CR54","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS et al (2000) Myasthenia gravis: recommendations for clinical research standards. Neurology 55(1):16\u201323","journal-title":"Neurology"},{"key":"10264_CR55","first-page":"45","volume-title":"Clinical neurology and neurosurgery monographs","author":"H Oosterhuis","year":"1984","unstructured":"Oosterhuis H (1984) Myasthenia gravis. Clinical neurology and neurosurgery monographs. Churchill Livingstone, Edinburgh, pp 45\u201350"},{"issue":"10","key":"10264_CR56","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1212\/WNL.33.10.1316","volume":"33","author":"UA Besinger","year":"1983","unstructured":"Besinger UA, Toyka KV, H\u00f6mberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A (1983) Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology. 33(10):1316","journal-title":"Neurology."},{"key":"10264_CR57","unstructured":"Dalby A, Kjar M, De Fine Olivarius B (1973) Continuous treatment of myasthenia gravis with prednisone. Myasthenia Gravis. Papers. pp. 164"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10264-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-020-10264-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10264-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T05:03:48Z","timestamp":1635915828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-020-10264-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,16]]},"references-count":57,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10264"],"URL":"https:\/\/doi.org\/10.1007\/s00415-020-10264-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,16]]},"assertion":[{"value":"21 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}